☆ 4.5 Article

Knowledge-map analysis of bladder cancer immunotherapy

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Multidisciplinary

BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity

Zhiyong Cai et al.

Summary: In order to improve the response rate of immune checkpoint blockade monotherapy (ICB), it is important to identify a potential target for combination therapy. Based on the analysis of tumor microenvironment (TME)-related indicators, it is confirmed that BCAT2 plays a role in shaping a noninflamed TME in bladder cancer. Multiomics analysis reveals that BCAT2 inhibits the recruitment of cytotoxic lymphocytes by suppressing proinflammatory cytokine/chemokine-related pathways and the T-cell-chemotaxis pathway. Immunoassays demonstrate a negative correlation between the secretion of CD8(+)T-cell-related chemokines and BCAT2, resulting in a decrease in the number of CD8(+)T cells around BCAT2(+) tumor cells. The combination of BCAT2 deficiency and anti-PD-1 antibody shows a synergistic effect in vivo, suggesting the potential of BCAT2 in combination therapy. Furthermore, the predictive value of BCAT2 in immunotherapy efficacy is validated in multiple immunotherapy cohorts.

ADVANCED SCIENCE (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8(+) T Cell-Mediated Anti-Cancer Immunity in Bladder Carcinoma

Huihuang Li et al.

Summary: A systematic multi-omics analysis identified S100A5 as a novel immunosuppressive target for bladder cancer. The expression of S100A5 inhibits CD8(+) T cell recruitment and cytotoxicity, leading to resistance to immune checkpoint blockade therapy. Targeting S100A5 enhances the infiltration and cytotoxicity of CD8(+) T cells, thereby enhancing the efficacy of immune checkpoint blockade therapy in bladder cancer.

ADVANCED SCIENCE (2023)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Urology & Nephrology

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Bernadett Szabados et al.

Summary: The results of the ABACUS trial showed that neoadjuvant atezolizumab in MIBC is associated with significant clinical responses and high DFS. CD8+ expression and serial ctDNA levels are correlated with outcomes and may contribute to personalized therapy in the future.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors

Fotis Nikolos et al.

Summary: Chemoimmunotherapy has shown limited clinical benefit in bladder cancer patients and the reasons for this are not well understood. This study reveals that platinum-based chemotherapy hinders the infiltration and activity of CD8+ T cells in mouse models of muscle-invasive bladder cancer. The release of prostaglandin E-2 (PGE(2)) from dying cancer cells is identified as a mechanism that inhibits dendritic cell maturation. By blocking PGE(2) release, CD8+ T cells regain their tumoricidal activity and infiltrate the tumor site. Blocking PGE(2) release synergizes with chemotherapy and enhances the response to immune checkpoint inhibitor therapy. These findings highlight the potential of targeting the COX-2/PGE2 axis in chemoimmunotherapy for bladder cancer.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer

Zheng Zhu et al.

Summary: The study found that photodynamic therapy with bladder cancer-specific porphyrin-based nanoparticles (PNP PDT) can enhance the efficacy of immune checkpoint inhibitors (ICI) for treating locally advanced and metastatic bladder cancer.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Escherichia coli-Specific CXCL13-Producing T-FH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Anne-Gaelle Goubet et al.

Summary: CD4+ T cells and PD-L1 expression are correlated with the efficacy of immunotherapy drugs, which is important for the treatment of bladder cancer patients.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Cell Biology

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

Jiao Hu et al.

Summary: This study compares the efficacy of different neoadjuvant treatments in patients with MIBC and suggests that neoadjuvant combination therapy based on tislelizumab provides the best results. The development of an efficacy prediction model helps identify patients who are suitable for neoadjuvant combination therapy. The study also indicates that patients achieving pathological complete response may be candidates for bladder preservation therapy.

CELL REPORTS MEDICINE (2022)

添加到收藏夹

Review Biology

Current status and future perspectives of immunotherapy in bladder cancer treatment

Zhangsong Wu et al.

Summary: The treatment strategy for bladder cancer has evolved with the introduction of immunotherapy, but only a limited number of patients benefit from it, and there are challenges with immune-related adverse events. If response rates improve and adverse events are managed better, immunotherapy could potentially revolutionize the landscape of urothelial carcinoma therapeutics.

SCIENCE CHINA-LIFE SCIENCES (2021)

添加到收藏夹

Article Oncology

Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer

John P. Sfakianos et al.

Summary: BCG vaccine is used for protection against tuberculosis and immunotherapy for bladder cancer, showing immune protection against Mycobacterium tuberculosis and non-tuberculosis related pathogens. Various studies indicate that BCG activates multiple immune pathways which contribute to immune response and efficacy in bladder cancer therapy.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

添加到收藏夹

Article Oncology

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

Niannian Ji et al.

Summary: The combination of oral rapamycin with BCG treatment for NMIBC patients is safe and well-tolerated, enhancing BCG-specific gamma delta T cell immunity and increasing urinary cytokines during BCG treatment. Further research is necessary to explore the long-term safety, tolerability, and efficacy effects of rapamycin in conjunction with BCG.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer

Shaoming Zhu et al.

Summary: The study found that genetic alterations along the PI3K pathway are common in advanced bladder urothelial cancer, and PI3K inhibition has a significant inhibitory effect on cancer cells. Combination therapy of pan-PI3K inhibition, anti-PD1 therapy, and PI3K inhibition combined with anti-PD1 therapy improved overall survival in mouse models with PTEN-deleted tumors, stimulating an immune response.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Immunology

Neoantigen: A New Breakthrough in Tumor Immunotherapy

Zheying Zhang et al.

Summary: Cancer immunotherapy enhances the body's immune response to target and eliminate cancer cells, with a focus on the emerging approach of tumor neoantigens. Studies have shown the relationship between neoantigens and T cell recognition of cancer cells, highlighting the potential of vaccines developed against these specific antigens in clinical trials.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Balar et al.

Summary: This study evaluated the efficacy and safety of pembrolizumab, a PD-1 inhibitor, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. The results showed that pembrolizumab monotherapy was well-tolerated and demonstrated promising antitumor activity in this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

D. F. Bajorin et al.

Summary: In a trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, adjuvant nivolumab showed longer disease-free survival compared to placebo, especially among patients with a PD-L1 expression level of 1% or more, despite an increase in treatment-related adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Metastasis of duodenal adenocarcinoma to the urinary bladder presenting as hematuria

Rani Tulsi et al.

JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

Jiao Hu et al.

Summary: Siglec15 is specifically overexpressed in the tumor microenvironment (TME) of various cancers, likely designing a non-inflamed TME in bladder cancer (BLCA). High expression of Siglec15 in BLCA correlates with lower immune infiltration, lower response to cancer immunotherapy, and a higher incidence of hyperprogression. A combination of anti-Siglec15 and cancer immunotherapy may be a more effective strategy than monotherapy, while an immune risk score (IRS) could accurately predict prognosis and response to treatment.

THERANOSTICS (2021)

添加到收藏夹

Article Urology & Nephrology

Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort

Chad R. Ritch et al.

JOURNAL OF UROLOGY (2020)

添加到收藏夹

Article Oncology

Blockade of DC-SIGNthorn Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer

Baoying Hu et al.

CANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives

Mikolaj Wolacewicz et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction

Brianna Burke et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Treatment of muscle-invasive and advanced bladder cancer in 2020

Vaibhav G. Patel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

添加到收藏夹

Article Oncology

Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study

M. Bandini et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Nick van Dijk et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Jianjun Gao et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Oncology

Intratumoral TIGIT+CD8+T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

Zhaopei Liu et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Liposome-Encapsulated Bacillus Calmette-Guerin Cell Wall Skeleton Enhances Antitumor Efficiency for Bladder Cancer In Vitro and In Vivo via Induction of AMP-Activated Protein Kinase

Young Mi Whang et al.

CANCERS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Thomas Powles et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

Andrea Necchi et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Urology & Nephrology

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

J. Alfred Witjes et al.

EUROPEAN UROLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun V. Balar et al.

LANCET (2017)

添加到收藏夹

Article Oncology

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun V. Balar et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J. Bellmunt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Biology

Improving Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model

Svetlana Bunimovich-Mendrazitsky et al.

MATHEMATICAL MEDICINE AND BIOLOGY-A JOURNAL OF THE IMA (2016)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg et al.

LANCET (2016)

添加到收藏夹

Article Computer Science, Interdisciplinary Applications

Scientific workflows for bibliometrics

Arzu Tugce Guler et al.

SCIENTOMETRICS (2016)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immunotherapy in Bladder Cancer

Monali Vasekar et al.

CURRENT MOLECULAR PHARMACOLOGY (2016)

添加到收藏夹

Article Urology & Nephrology

Bacillus Calmette-Guerin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy

Cyrill A. Rentsch et al.

EUROPEAN UROLOGY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Thomas Powles et al.

NATURE (2014)

添加到收藏夹

Review Urology & Nephrology

The mechanism of action of BCG therapy for bladder cancer-a current perspective

Gil Redelman-Sidi et al.

NATURE REVIEWS UROLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Bacillus Calmette-Guerin (BCG) Infection Following Intravesical BCG Administration as Adjunctive Therapy For Bladder Cancer Incidence, Risk Factors, and Outcome in a Single-Institution Series and Review of the Literature

Maria Asuncion Perez-Jacoiste Asin et al.

MEDICINE (2014)

添加到收藏夹

Article Microbiology

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer

Kathrin Buffen et al.

PLOS PATHOGENS (2014)

添加到收藏夹

Article Urology & Nephrology

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Jorg Oddens et al.

EUROPEAN UROLOGY (2013)

添加到收藏夹

Article Oncology

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

Bradley C. Carthon et al.

CLINICAL CANCER RESEARCH (2010)

添加到收藏夹

Article Urology & Nephrology

Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

Rui Fa Han et al.

UROLOGY (2006)

添加到收藏夹

Review Pharmacology & Pharmacy

Bibliometric methods: Pitfalls and possibilities

JA Wallin

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)

添加到收藏夹

Article Oncology

Bacillus Calmete-Guerin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

JS Lam et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2003)

添加到收藏夹

Article Urology & Nephrology

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials

RJ Sylvester et al.

JOURNAL OF UROLOGY (2002)

添加到收藏夹

Article Urology & Nephrology

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study

DL Lamm et al.

JOURNAL OF UROLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.